BioCryst Pharmaceuticals, Inc. (BCRX) Q4 2009 Earnings Results

BioCryst Pharmaceuticals Beats on EPS, Stock Down 3.32%

BioCryst Pharmaceuticals reported a significant earnings surprise on EPS, but the stock fell by 3.32% in reaction. Investors may have been disappointed by the lack of revenue details and forward guidance. The management's cautious optimism suggests they are focused on long-term growth despite short-term uncertainties.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$0.37	N/A	+374.36%
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management expressed confidence in the company's future prospects despite not providing specific guidance. They focused on the potential of their ongoing projects.

Management highlighted strong performance in their product pipeline.

They emphasized the importance of continued investment in R&D.

BioCryst Pharmaceuticals Beats on EPS, Stock Down 3.32%

Key numbers

Management commentary

BioCryst Pharmaceuticals, Inc.

More earnings this week

BioCryst Pharmaceuticals Beats on EPS, Stock Down 3.32%

Key numbers

Management commentary